Dehydrozingerone

Dehydrozingerone

SCHEMBL498223

COc1cc(/C=C/C(C)=O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 1.00
CYP2D6 P10635 3/20 0.79
NFKB1 P19838 3/20 0.79
CYP1A2 P05177 2/20 0.79
ALOX5 P09917 2/20 0.79
HSD11B1 P28845 2/20 0.79
STAT3 P40763 2/20 0.79
NFKB2 Q00653 2/20 0.79
RELA Q04206 2/20 0.79
NFE2L2 Q16236 2/20 0.79
KDM4E B2RXH2 2/20 0.77
CA12 O43570 2/20 0.77
CA1 P00915 2/20 0.77
CA2 P00918 2/20 0.77
CA3 P07451 2/20 0.77
PKM P14618 2/20 0.77
CA4 P22748 2/20 0.77
CA6 P23280 2/20 0.77
CA5A P35218 2/20 0.77
SNCA P37840 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dehydrozingerone SCHEMBL30310276 1.00 APP (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL29691993 1.00 APP (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL498224 1.00 APP (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL9104958 0.98 APP (0.97) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL27764046 0.91 APP (0.83) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL29478095 0.88 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL1493283 0.88 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL1493282 0.88 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL30668505 0.88 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL9907021 0.88 APP (0.78) APPCYP2D6NFKB1CYP1A2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130864-A1 METHOD AND COMPOSITION FOR ENHANCING EXERCISE PERFORMANCE NANJING NUTRABUILDING BIO TECH CO LTD (CN) 2026-05-14 US claimed
US-20250327100-A1 Strain of Pseudomonas Putida Genetically Modified to Express a Benzalacetone Reductase BGENE GENETICS (FR) 2025-10-23 US claimed
US-20250033082-A1 METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS ADAMA MAKHTESHIM LTD. (IL) 2025-01-30 US claimed
EP-4464696-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD FOR PREPARING SAME, EPOXY COMPOSITE MATERIAL COMPRISING SAME, AND DECOMPOSITION METHOD THEREOF Konkuk University Industrial Cooperation Corp. (KR) 2024-11-20 EP claimed
CN-118201991-A Methods and compositions for reducing solvent release from agrochemical formulations and reducing agrochemical formulation odor 安道麦马克西姆有限公司 2024-06-14 CN claimed
EP-4370674-A1 STRAIN OF PSEUDOMONAS PUTIDA GENETICALLY MODIFIED TO EXPRESS A BENZALACETONE REDUCTASE BGene Genetics (FR) 2024-05-22 EP claimed
CN-117653618-A Novel benzalacetone derivative and use thereof 韩药有限公司 2024-03-08 CN claimed
US-20230364069-A1 METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS (KR) 2023-11-16 US claimed
US-20230365742-A1 CHEMICALLY DEGRADABLE EPOXY COMPOUND, METHOD OF PREPARING SAME COMPOUND, EPOXY COMPOSITE MATERIAL CONTAINING SAME COMPOUND, AND METHOD OF DEGRADING SAME COMPOSITE MATERIAL KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) 2023-11-16 US claimed
EP-4248957-A1 METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-? RECEPTOR INHIBITOR University Industry Foundation, Yonsei University Wonju Campus (KR) 2023-09-27 EP claimed
EP-1433469-B1 Composition for dyeing keratinous fibres HENKEL KGAA (DE) 2006-10-11 EP claimed
US-7105032-B2 Agents used for dyeing keratinous fibers HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2006-09-12 US claimed
EP-1434557-B1 AGENT FOR THE COLORATION OF KERATIN-CONTAINING FIBERS HENKEL KGAA (DE) 2005-11-09 EP claimed
US-20050144740-A1 Agents used for dyeing keratinous fibers HENKEL AG & CO. KGAA (DE) 2005-07-07 US claimed
EP-1292268-B1 AGENT FOR DYEING KERATIN CONTAINING FIBERS HENKEL KGAA (DE) 2005-02-23 EP claimed
EP-1292269-B1 AGENT FOR DYEING KERATIN CONTAINING FIBERS HENKEL KGAA (DE) 2005-02-09 EP claimed
US-6576660-B1 Treating prostate cancer, breast cancer, obesity, skin disorders and baldness ARCH DEVELOPMENT CORPORATION 2003-06-10 US claimed
US-20030082116-A1 Adhesive compositions containing dual function stabilizers and active agents CLOSURE MEDICAL CORPORATION (US) 2003-05-01 US claimed
US-6117223-A Hot melt inks containing polyketones XEROX CORPORATION (US) 2000-09-12 US claimed
WO-1995018606-A9 CURCUMIN, ANALOGUES OF CURCUMIN AND NOVEL USES THEREOF 1997-05-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050144740-A1 Agents used for dyeing keratinous fibers KRT18, TUBB3, DSG1 APP 2519/4885CYP2D6 2331/4885NFKB1 2636/4885
US-20260130864-A1 METHOD AND COMPOSITION FOR ENHANCING EXERCISE PERFORMANCE SLC6A3, IL17A, HSD17B13 APP 2617/4885CYP2D6 679/4885NFKB1 3463/4885
US-20030082116-A1 Adhesive compositions containing dual function stabilizers and active agents TLN1, PTK2, ILK APP 2366/4885CYP2D6 4812/4885NFKB1 2471/4885
US-20230364069-A1 METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR TGFBR2, TGFBR1, TGFB1 APP 478/4885CYP2D6 1867/4885NFKB1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.